Our Team
Alexander Real, MD, PhD
 |
Education |
- Radiation Oncology Residency, University of California San Francisco (2023-2027)
- Transitional Year Residency, Memorial Sloan Kettering Cancer Center (2022-2023)
- M.D., Icahn School of Medicine at Mount Sinai (2014-2022)
- Ph.D., Cancer Biology, Icahn School of Medicine at Mount Sinai (2014-2022)
- M.S., Materials Science and Engineering, Stanford University (2013-2014)
- B.S., Bioengineering of Materials, Stanford University (2008-2012)
- B.A., English Literature, Stanford University (2008-2012)
 |
Awards & Honors |
- Ruth L. Kirschstein National Research Service Award (NIH F30)
- Portland Press Best Poster Prize, 2018
- Invited Speaker, EMBO Pseudoenzymes Conference, Sardinia Italy, 2018
 |
Selected Publications, Abstracts, and Posters |
- Z. M. Khan*, A. Real*, W. Marsiglia*, M. Duffy, A. Chow, J. R. Yerabolu, A. P. Scopton, and A. C. Dar. Structural basis for the action of the anticancer drug trametinib at KSR-bound MEK. Nature. 2021
- R. H.B Smith, Z.M. Kahn, P.M. Ung, A. Scopton, L. Silber, S. M. Mack, A. Real, A. Schlessinger, A. C. Dar. Type II Binders Targeting the “GLR-out” Conformation of the Pseudokinase STRADα. Biochemistry. 2021
- M. Sonoshita, A. P. Scopton, P. M-U. Ung, M. A. Murray. L. Silber, A. Y. Maldonado, A. Real, A. Schlessinger, R. L. Cagan, and A. C. Dar. A whole animal platform to advance a clinical kinase inhibitor into new disease space. Nature Chemical Biology. 2018
- A. Real, S. Hong, P. Pissios. Nicotinamaide N-Oxidation by CYP2E1 in Human Liver Microsomes. Drug Metabolism and Disposition. 2013
- A. Real, A.C. Dar. A High-Throughput Screen to Identify Potent Ligands of the Pseudokinase KSR. EMBO Pseudoenzymes Conference, Sardinia Italy, 2018